Substance P

Substance P

Substance P
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
 N  (: YesY/N?)

Substance P (SP) is an undecapeptide (a peptide composed of a chain of 11 amino acid residues) member of the tachykinin neuropeptide family. It is a neuropeptide, acting as a neurotransmitter and as a neuromodulator.[2][3] Substance P and its closely related neurokinin A (NKA) are produced from a polyprotein precursor after differential splicing of the preprotachykinin A gene. The deduced amino acid sequence of substance P is as follows:[4]

with an amidation at the C-terminus.[5] Substance P is released from the terminals of specific sensory nerves. It is found in the brain and spinal cord and is associated with inflammatory processes and pain. In 2014, the role of substance P to male aggression in fruit flies was identified.[6]


  • Biographical sketch 1
  • Hart's students 2
  • The Concept of Law 3
  • Other work 4
  • Writings 5
  • Festschrift 6
  • See also 7
  • References 8
  • Sources 9
  • External links 10


The original discovery of Substance P (SP) was in 1931 by Ulf von Euler and John H. Gaddum as a tissue extract that caused intestinal contraction in vitro.[7] Its tissue distribution and biologic actions were further investigated over the following decades.[2] The eleven-amino-acid structure of the peptide was determined by Susan Leeman in 1971.[8]

In 1983, NKA (previously known as substance K or neuromedin L) was isolated from porcine spinal cord and was also found to stimulate intestinal contraction.[9]


The endogenous receptor for substance P is neurokinin 1 receptor (NK1-receptor, NK1R).[10] It belongs to the tachykinin receptor sub-family of GPCRs.[11] Other neurokinin subtypes and neurokinin receptors that interact with SP have been reported as well. Amino acid residues that are responsible for the binding of SP and its antagonists are present in the extracellular loops and transmembrane regions of NK-1. Binding of SP to NK-1 results in internalization by the clathrin-dependent mechanism to the acidified endosomes where the complex disassociates. Subsequently, SP is degraded and NK-1 is re-expressed on the cell surface.[12] Substance P and the NK1 receptor are widely distributed in the brain and are found in brain regions that are specific to regulating emotion (hypothalamus, amygdala, and the periaqueductal gray).[13] They are found in close association with serotonin (5-HT) and neurons containing norepinephrine that are targeted by the currently used antidepressant drugs.[1] The SP receptor promoter contains regions that are sensitive to cAMP, AP-1, AP-4, CEBPB,[14] and epidermal growth factor. Because these regions are related to complexed signal transduction pathways mediated by cytokines, it has been proposed that cytokines and neurotropic factors can induce NK-1. Also, SP can induce the cytokines that are capable of inducing NK-1 transcription factors.[15]


Substance P is an important element in pain perception. The sensory function of substance P is thought to be related to the transmission of pain information into the central nervous system. Substance P coexists with the excitatory neurotransmitter glutamate in primary afferents that respond to painful stimulation.[16] Substance P has been associated with the regulation of mood disorders, anxiety, stress,[17] reinforcement,[18] neurogenesis,[19] respiratory rhythm,[20] neurotoxicity, nausea and emesis,[21] pain, and nociception.[22] Substance P and other sensory neuropeptides can be released from the peripheral terminals of sensory nerve fibers in the skin, muscle, and joints. It is proposed that this release is involved in neurogenic inflammation, which is a local inflammatory response to certain types of infection or injury.[23] The regulatory function of SP also involves the regulation of its high-affinity receptor, NK-1. Substance P receptor antagonists may have important therapeutic applications in the treatment of a variety of stress-related illnesses, in addition to their potential as analgesics.


The vomiting center in the medulla called the Area Postrema, contains high concentrations of substance P and its receptor, in addition to other neurotransmitters such as choline, histamine, dopamine, serotonin, and opioids. Their activation stimulates the vomiting reflex. Different emetic pathways exist, and substance P/NK1R appears to be within the final common pathway to regulate vomiting.[24]


Substance P is involved in nociception, transmitting information about tissue damage from peripheral receptors to the central nervous system to be converted to the sensation of pain. It has been theorized that it plays a part in fibromyalgia. Capsaicin has been shown to reduce the levels of substance P, it is presumed, by reducing the number of C-fibre nerves or causing these nerves to be more tolerant. Thus, capsaicin is used clinically as an analgesic and an anti-inflammatory agent to reduce pain associated with arthritis and many types of neuralgia. A role of substance P and NKA in nociception is suggested by the reduction in response thresholds to noxious stimuli by central administration of K2 and K3 agonists. Based on recent studies, it was proposed that NK1, and possibly NK2 receptor antagonists, could be developed as analgesic drugs.

It has been studied that the mice carrying a disruption of the gene encoding SP/NKA show severely reduced nociceptive pain responses when the stimuli are moderate to intense. Pain behaviors induced by mechanical, thermal, and chemical stimulation of somatic and visceral tissues were reduced in the mutant mice lacking SP/NKA. However, it has been proposed that the importance of SP and NKA in animal pain responses apply only to a certain 'window' of pain intensities, and, when the intensity of the pain stimuli is further increased, the responses of the knockout mice is not severely different from the wild-type mice.[16]

Substance P increases glutamate activity (NMDA) in central nervous system, and it is associated with the development of brain edema and functional deficits after traumatic brain injury.[25]

Cell growth

Substance P has been known to stimulate cell growth in culture,[26] and it was shown that substance P could promote wound healing of non-healing ulcers in humans.[27]


Substance P also has effects as a potent vasodilator. Substance P-induced vasodilatation is dependent on nitric oxide release.[28] Substance P is involved in the axon reflex-mediated vasodilatation to local heating and wheal and flare reaction. It has been shown that vasodilatation to substance P is dependent on the NK1 receptor located on the endothelium. In contrast to other neuropeptides studied in human skin, substance P-induced vasodilatation has been found to decline during continuous infusion. This possibly suggests an internalization of neurokinin-1 (NK1).[29] As is typical with many vasodilators, it also has bronchoconstrictive properties, administered through the non-adrenergic, non-cholinergic nervous system (branch of the vagal system).

Clinical significance

Elevation of serum, plasma, or tissue SP and/or its receptor (NK1R) has been associated with many diseases: sickle cell crisis;[30] inflammatory bowel disease;[31][32] major depression and related disorders;[33][34][35] fibromyalgia;[36] rheumatological;[37] and infections such as HIV/AIDS and respiratory syncytial virus,[38] as well as in cancer.[39][40]

When assayed in the intact human, the observed variability of the SP concentrations are large, and in some cases the assay methodology is questionable.[41] SP concentrations cannot yet be used to diagnose disease clinically or gauge disease severity. It is not yet known whether changes in concentration of SP or density of its receptors is the cause of any given disease, or its effect.

As increasingly documented, the SP-NK1R system induces or modulates many aspects of the immune response, including WBC production and activation, and cytokine expression.[42] Reciprocally, cytokines may induce expression of SP and its NK1R.[43][44] In this sense, for diseases in which a pro-inflammatory component has been identified or strongly suspected, and for which current treatments are absent or in need of improvement, abrogation of the SP-NK1 system continues to receive focus as a treatment strategy. Currently, the only completely developed method available in that regard is antagonism (blockade, inhibition) of the SP preferring receptor, i.e., by drugs known as neurokinin type 1 antagonists (also termed: SP antagonists, or tachykinin antagonists.) One such drug is aprepitant to prevent the nausea and vomiting that accompanies chemotherapy, typically for cancer.

With the exception of chemotherapy-induced nausea and vomiting, the patho-physiological basis of many of the disease groups listed below, for which NK1RAs have been studied as a therapeutic intervention, are to varying extents hypothesized to be initiated or advanced by a chronic non-homeostatic inflammatory response.[42][45][46][47][48]

Chemotherapy Induced Nausea and Vomiting

see: Chemotherapy-induced nausea and vomiting and Aprepitant

In line with its role as a first line defense system, SP is released when toxicants or poisons come into contact with a range of receptors on cellular elements in the chemoreceptor trigger zone, located in the floor of the fourth ventricle of the brain, the (area postrema). Presumably, SP is released in or around the Nucleus of the Solitary Tract upon integrated activity of dopamine, serotonin, opioid, and/or acetylcholine receptor signaling. NK1Rs are stimulated. In turn, a fairly complex reflex is triggered involving cranial nerves sub-serving respiration, retroperistalsis, and general autonomic discharge.


High levels of BDNF and substance P have been found associated with increased itching in eczema.[49][50]

Entamoeba Histolytica

Entamoeba histolytica is a unicellular parasitic protozoan that infects the lower gastrointestinal tract of humans. The symptoms of infection are diarrhea, constipation, and abdominal pain.[51][52] This protozoan was found to secrete serotonin[53] as well as substance P and neurotensin.[54]


Denervation supersensitivity

When the innervation to substance P nerve terminals is lost, post-synaptic cells compensate for the loss of adequate neurotransmitter by increasing the expression of post-synaptic receptors. This, ultimately, leads to a condition known as denervation supersensitivity as the post-synaptic nerves will become hypersensitive to any release of substance P into the synaptic cleft.

Male aggression

A suggestion of a link to male aggression was made in 2014. Confirmed in male fruit flies and discussed as a possibility in other species, even humans, who also have the gene that produces substance P, by neuroscientist David J. Anderson and others at California Institute of Technology researching "deep evolutionary roots of very fundamental behaviors".[55] Clues found in the brains of fruit flies might lead to further research that reveals the role of substance P in similar behavior in those other species.


  1. ^
  2. ^ Matthew H. Kramer and Claire Grant (2008). "Introduction", in Satthew H. Kramer, Claire Grant, Ben Colburn, and Anthony Hatzistavrou (ed.): The Legacy of H.L.A. Hart: Legal, Political and Moral Philosophy. Oxford/New York, Oxford University Press, xiii.
  3. ^ Mullender, Richard: – H.L.A. Hart in Anglo-American Context"A Life of H.L.A. Hart: the Nightmare and the Noble Dream"Nicola Lacey, , Web Journal of Current Legal Issues (review 2007). Oxford University Press, (2004). ISBN 978-0-19-920277-5
  4. ^ a b c d e
  5. ^ Biography of Jenifer Hart
  6. ^ Obituary of Jenifer Hart, Daily Telegraph, 9 April 2005
  7. ^ Margaret Howatson Obituary: Jenifer Hart, The Independent, 31 March 2005
  8. ^
  9. ^ Hart. H. L. A. "Immorality and Treason·, The Listener (July 30, 1959). 162-63. Reprinted in Wasserstrom, Richard A. (ed.). Morality and the Law. Belmont, CA: Wadsworth Publishing, 1971.

External links

  • Fight Club for Flies video, Science Take, New York Times, February 3, 2014